Vanguard Fiduciary Trust
ACTU

Vanguard Fiduciary Trust’s Actuate Therapeutics ACTU Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$83.4K Sell
54,497
-8,095
-13% -$18.8K ﹤0.01% 3770
2026
Q1 		$172K Buy
+62,592
New +$259K ﹤0.01% 3560

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM
RCG
Rock Creek Group Washington, District of Columbia $994M AUM 11.29% 1-Year Est. Return

Vanguard Fiduciary Trust's ACTU Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Actuate Therapeutics (ACTU) stake by 13% in Q2 2026, selling an estimated $18.8K and leaving 54,497 shares worth $83.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3770.

Vanguard Fiduciary Trust first reported a position in ACTU in Q1 2026 and has held it in 2 quarters since. The position peaked at $172K in Q1 2026. 62 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Vanguard Fiduciary Trust held 54,497 shares of Actuate Therapeutics worth $83.4K as of Q2 2026.
  • Vanguard Fiduciary Trust sold 8,095 Actuate Therapeutics shares in Q2 2026, an estimated $18.8K.
  • Actuate Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3770 holding.
  • Vanguard Fiduciary Trust first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Actuate Therapeutics position peaked at $172K in Q1 2026.
  • 62 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.